Vascular Biogenics LTD. – Ordinary Shares (NASDAQ:VBLT) Sellers Decreased By 17.44% Their Shorts As Of Jun 27, 2018

June 27, 2018 - By Rebecca Betts

Vascular Biogenics Ltd. (NASDAQ:VBLT) Corporate Logo

Vascular Biogenics LTD. – Ordinary Shares (NASDAQ:VBLT) registered a decrease of 17.44% in shares shorted. FINRA published shares shorted of VBLT’s total 436,600 shares. That’s 17.44% down from 528,800 shares. 4 days will cost VBLT with 116,500 average volume to restore its former position. 3.07% is Vascular Biogenics LTD. – Ordinary Shares float short.

VBLT is hitting $2.3 during the last trading session, after decreased 1.08%.Vascular Biogenics Ltd. has volume of 30,895 shares. Since June 27, 2017 VBLT has declined 60.91% and is downtrending. The stock underperformed the S&P 500 by 73.48%.

Vascular Biogenics Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for cancer.The firm is valued at $68.76 million. The company??s program is based on its proprietary vascular targeting system platform technology, which utilizes genetically targeted therapy to destroy newly formed or angiogenic blood vessels.Last it reported negative earnings. The Company’s lead product candidate is VB-111, a gene biologic that is in Phase III clinical trials for the treatment of recurrent glioblastoma, an aggressive form of brain cancer; and has completed Phase II clinical trials for recurrent platinum-resistant ovarian cancer, as well as for iodine-resistant differentiated thyroid cancer.

Vascular Biogenics Ltd. (NASDAQ:VBLT) Ratings Coverage

Total analysts of 4 have positions in Vascular Biogenics (NASDAQ:VBLT) as follows: 0 rated it a “Buy”, 0 with “Sell” and 4 with “Hold”. The positive are 0. Since March 8, 2018 according to StockzIntelligence Inc Vascular Biogenics has 6 analyst reports. The company rating was downgraded by JMP Securities on Thursday, March 8. On Thursday, March 8 the stock of Vascular Biogenics Ltd. (NASDAQ:VBLT) has “Neutral” rating given by H.C. Wainwright. On Friday, May 18 H.C. Wainwright maintained Vascular Biogenics Ltd. (NASDAQ:VBLT) rating. H.C. Wainwright has “Hold” rating and $300 target. On Thursday, March 22 H.C. Wainwright maintained Vascular Biogenics Ltd. (NASDAQ:VBLT) with “Hold” rating. The company rating was downgraded by Piper Jaffray on Thursday, March 8. On Friday, March 9 the stock has “Neutral” rating by Chardan Capital Markets.

For more Vascular Biogenics Ltd. (NASDAQ:VBLT) news posted recently go to: Streetinsider.com, Streetinsider.com, Benzinga.com, Streetinsider.com or Nasdaq.com. The titles are as follows: “Pre-Open Movers 06/06: (AXON) (VBLT) (SIG) Higher; (AMBA) (IMGN) (OLLI) Lower (more…)” posted on June 06, 2018, “VBL Therapeutics (VBLT) Prices 5.9M Share Registered Direct Offering at $2.50/Sh” on June 26, 2018, “40 Stocks Moving In Tuesday’s Mid-Day Session” with a publish date: June 26, 2018, “VBL Therapeutics (VBLT) Presents Positive Data on its MOSPD2 Platform Technology” and the last “VBL Therapeutics Presents Positive Data on its MOSPD2 Platform Technology in Oncology and Inflammation at BIO 2018” with publication date: June 05, 2018.

Vascular Biogenics Ltd. (NASDAQ:VBLT) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: